FDA DMB Acknowledgment Letter to Aurobindo Pharma USA, Inc.
Summary
FDA's Division of Manufacturing and Biotechnology (DMB) issued an acknowledgment letter to Aurobindo Pharma USA, Inc. in connection with submission FDA-2026-P-4566. The document was filed under CDER (Center for Drug Evaluation and Research) authorship on Regs.gov. No documents are available for viewing or download, indicating this may be a procedural filing or pre-submission acknowledgment.
About this source
Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.
What changed
This document records FDA's acknowledgment of a submission from Aurobindo Pharma USA, Inc. filed under docket FDA-2026-P-4566. The source metadata confirms CDER as the authoring center but provides no substantive content.
Affected parties tracking FDA submissions for Aurobindo Pharma should note this docket appears on Regs.gov as an active filing. Without access to the attachment (attachment_1.pdf), the nature and scope of the submission cannot be determined from this source.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
There are no documents available to view or download
Attachments 1
Acknowledgment Letter from FDA DMB to Aurobindo Pharma USA, Inc.
More Information
- Author(s) CDER
Download
Mentioned entities
Parties
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.